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Abstract
Background: Atherosclerosis is an inflammatory disease that is marked by increased presence of Tumor Necrosis
Factor-alpha (TNFa), increased expression of Vascular Cell Adhesion Molecule-1 (VCAM-1), increased presence of
serum monocytes and activation of the canonical inflammatory molecule, Nuclear Factor Kappa-B (NFB).
Hyperinsulinemia is a hallmark of insulin resistance and may play a key role in this inflammatory process.
Methods: Using Western blot analysis, immunocytochemistry, flow cytometry and biochemical inhibitors, we
measured changes in VCAM-1 protein expression and NFB translocation in vascular endothelial cells in the
presence of TNFa and/or hyperinsulinemia and in the absence or presence of kinase pathway inhibitors.
Results: We report that hyperinsulinemia augmented TNFa stimulated increases in VCAM-1 protein greater than
seen with TNFa alone and decreased the time in which VCAM-1 translocated to the cell surface. We also observed
that in the presence of Wortmannin, a biochemical inhibitor of phosphatidylinositol 3-kinase (a hallmark of insulin
resistance), VCAM-1 expression was greater in the presence of TNFa plus insulin as compared to that seen with
insulin or TNFa alone. Additionally, nuclear import of NFB occurred sooner in the presence of insulin and TNFa
together as compared to each alone, and in the presence of Wortmannin, nuclear import of NFB was greater
than that seen with insulin and TNFa alone.
Conclusions: hyperinsulinemia and insulin resistance appear to augment the inflammatory effects of TNFa on
VCAM-1 expression and NFB translocation, both of which are markers of inflammation in the vasculature.
Keywords: Tumor necrosis factor-alpha, inflammation, Vascular Adhesion Molecule-1, Nuclear Factor kappa-B,
hyperinsulinemia, atherosclerosis
Introduction
Type-2 Diabetes Mellitus (T2DM) is a constellation of
disorders that includes, but is not limited to, hyperinsu-
linemia, dyslipidemia and insulin resistance. These
pathologies are risk factors for retinopathy, neuropathy
and cardio-vascular events, to name a few [1]. Vascular
complications are the leading cause of morbidity and
mortality in patients with diabetes.
Atherosclerosis is a major consequence of vascular
dysfunction and in part comes from a collection of
players that leads to, vascular smooth cell proliferation,
lack of vascular compliance, endothelial cell remodeling,
and increased response to inflammatory cytokines. One
particular characteristic of atherogenesis is the increased
expression of cellular adhesion molecules (CAMs) at the
surface of vascular endothelial cells [2-4].
Although insulin is considered to be an anti-athero-
genic hormone [5], other studies have suggested that
long-term (i.e., chronic) insulin resistance accompanied
by hyperinsulinemia contributes to the pathogenesis of
atherosclerosis by augmenting the effects of inflamma-
tory cytokines, thereby significantly increasing the
expression of CAMs [6-11].
One such cytokine is tumor necrosis factor-alpha
(TNFa). TNFa is secreted by mature macrophages and
endothelial cells during the progression of atherosclerosis.
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[12], and many of these events are mediated in part by the
pathways associated with extracellular signal-regulated
kinases (ERK), c-jun N-terminal kinases (JNK) and nuclear
factor kappa-B (NFB) [13].
Among a myriad of effects, TNFa stimulates the
increased expression of the cellular adhesion molecule,
vascular cell adhesion molecule-1 (VCAM-1) [14]. In
response to TNFa, upregulation of VCAM-1 increases
the likelihood that serum-associated monocytes will
adhere to the arterial endothelium, transmigrate from
the intima to the media, and secrete both TNFa and
other inflammatory cytokines; essentially promoting a
positive feed-back process.
The question remains, however, does insulin in the
context of insulin resistance/hyperinsulinemia exacerbate
or mitigate the existing conditions of TNFa-stimulated
VCAM-1 expression? Moreover, what are the molecular
mechanism(s) that play a role in this process? Insulin
resistance is frequently defined in molecular terminology
as a post-insulin receptor dysfunction. It is commonly
believed that perturbation of the phosphatidylinositol-3
kinase (PI3K) and Akt signal pathway leads to dysfunc-
tion in intracellular insulin signaling: a down regulation
of translocation of glucose transporters to the membrane
and decreased uptake of glucose. Yet, there may be other
effects of this perturbation. Moreover, PI3K-independent
pathways may play significant roles in the dysregulation
of insulin signaling and inflammatory effects.
This study was performed in order to determine
whether or not hyperinsulinemia increases the effects of
TNFa-stimulated expression of VCAM-1 above that
seen for TNFa alone and which molecular pathways in
particular mediate this effect. We report here that insu-
lin- and TNFa-stimulated VCAM-1 expression appears
to be regulated by the c-jun N-terminal kinase pathway
as demonstrated by decreased VCAM-1 expression.
Additionally, hyperinsulinemia augments TNFa-stimu-
lated VCAM-1 expression above that seen for TNFa
alone. Third, inhibition of the PI3K pathway, a hallmark
of insulin signaling dysregulation, significantly increased
insulin plus TNFa induced VCAM-1 expression; thus,
implicating the pleiotropic effects of the PI3K pathway.
Finally, we not only show that insulin or TNFa alone
stimulate nuclear import of NFB, but also show that in
t h ep r e s e n c eo fi n s u l i na n dT N F a together, there are
greater amounts of NFB translocated to the nucleus
and sooner than seen with insulin- or TNFa-stimulated
NFB alone.
Methods
2.1. Materials
All general lab reagents were purchased from Sigma-
Aldrich (St. Louis, MO.). Primary antibodies to VCAM-
1 proteins were from Cell Signaling Technology (Boston,
MA) and BD Biosciences (San Jose, CA). Primary anti-
bodies to NFB p65 (Cat# 4764) were from Cell Signal-
ing (Boston, MA). PVDF membranes and other Western
blot accessories were from GE Healthcare/Amersham
(Piscataway, NJ) and the secondary HRP-conjugated and
FITC-conjugated antibodies were from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). Vascular endothelial
cells (VEC) were rat aorta vascular cells purchased from
ATCC (Manassas, VA) (Cat# CRL 1446) and maintained
in culture medium from Gibco/Invitrogen (Carlsbad,
CA). Kinase inhibitors PD98059 (for MEK1/2) and
Wortmannin (for PI3K) were from Cell Signaling (Dan-
vers, MA). SB203580 (p38 MAPK inhibitor) and
SP600125 (JNK inhibitor) were from EMD/Calbiochem
(Gibbstown, NJ). TNFa was from Roche Applied
Science (Indianapolis, IN) and insulin was from Sigma-
Aldrich (St. Louis, MO). NE-PER nuclear extraction kit
(Cat# P78835) was from Thermo-Fisher (Pittsburg, PA).
2.2. Cell Culture
VEC were cultured in growth medium [DMEM with 4
mM L-glutamine modified by ATCC to contain 4.5 g/L-
glucose, 1.5 g/L sodium bicarbonate and supplemented
with 10% heat-inactivated fetal bovine serum (Gibco/
Invitrogen, Carlsbad, CA) and 1% Antimycotic-Antibio-
tic solution (Gibco)] and cultured at 37°C, 5% CO2
atmosphere from passages 1 - 10. VEC were then cul-
tured in serum-free medium (SFM) for 24 h, pre-treated
in the absence or presence of indicated inhibitors for an
additional hour, and then incubated in SFM without or
with insulin (10 nM) or TNFa (20 ng/mL) alone or in
combination for designated times.
2.3 SDS-PAGE and Western Blot Analysis and Protein
Expression
VEC were cultured in SFM for 24 h before any treat-
ments were performed. Thereafter, cell monolayers were
treated with or without designated inhibitors for one
hour and then treated with insulin (10 nM), TNFa (20
ng/mL) or a combination of both for indicated times.
Whole cell lysates were prepared using lysis buffer (50
mM HEPES, 150 mM NaCl, 15 mM MgCl2,1m M
PIPES, 1 mM NaHPO4,1m MD T T ,1m MN aV a n a -
date, 1% TX-100, 0.05% SDS, 10 μg/mol Aprotinin, and
10 μg/mol Leupeptin). Lysates were cleared and protein
concentrations were determined in order to load lanes
with equal amounts of protein. Equal protein amounts
were placed in 2 × Laemmli Sample Buffer, frozen over-
night and then boiled for 5 minutes just before use.
Forty microliters of cleared lysates plus sample buffer
were loaded into each well of an 8-16% Pierce Precise
Protein gel (Thermo-Fisher, Waltham, MA) and were
run in 1 × Tris/HEPES/SDS running buffer at 100 V for
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nitrocellulose membranes (Millipore, Billerica, MA),
using a standard wet transfer protocol. After completion
of protein transfer, membranes were washed two times
in 1 × tris-buffered saline-tween (TBS-T) solution for 10
min. Membranes were then incubated in 5% bovine
serum albumin (BSA) in 1 × TBS-T blocking solution
f o r2ha tr o o mt e m p e r a t u r e ,w a s h e d2t i m e si n1×
TBS-T for 5 min and then incubated with a designated
primary antibody solution (1:1000 in 1% BSA/TBS-T)
overnight at 4°C. Membranes were washed 3 times with
TBS-T and then incubated with a designated secondary
antibody (1:2000 in 1% BSA/TBS-T) conjugated with
horseradish peroxidase at room temperature for 2
hours. Membranes were washed 2 times with TBS-T for
10 min at room temperature and washed once with 1 ×
TBS for 10 min. One milliliter of ECL (GE/Amersham)
detection solution was added to each membrane and
incubated for 1 min. Excess ECL was removed and
membranes were exposed to HyperFilm (GE/Amer-
sham) for visualization of proteins. Densitometry analy-
sis was performed using the ImageQuant TL v2005
(GE/Amersham) software program in order to quanti-
tate profile bands on representative films.
2.4 Immunofluorescence
Immunfluorescence (IF) was performed to visualize the
expression of VCAM-1 in VEC. VEC were cultured in
6-well plates containing BD Coat Coverslips (BD Bios-
ciences, San Jose, CA) in complete growth medium.
Subsequently, VEC were pre-incubated in serum-free
medium (SFM) for 24 hours then treated without or
with designated inhibitors and cytokines. After treat-
ments, cells were rinsed twice with PBS then fixed
with 2% paraformaldehyde for 15 min at room tem-
perature. After fixation, cells were washed three times
with PBS for 10 min at room temperature, washed
once with 70% ethanol/PBS, once with 95% ethanol,
and once with 100% ethanol each for 5 minutes at
room temperature. Cells were then blocked with 10%
Normal Donkey Serum solution for 2 h. VCAM-1
expression was detected using rabbit anti-VCAM-1
antibodies (Santa Cruz, CA) primary antibodies (1:50)
and FITC-conjugated donkey anti-rabbit IgG (Santa
Cruz Biotechnology, Santa Cruz, CA) secondary anti-
bodies (1:100). Secondary antibodies alone were used
to test for non-specific binding. After antibody stain-
ing, coverslips were then mounted on glass slides with
Prolong Gold Anti-Fade Reagent (Invitrogen, Carlsbad,
CA) and allowed to cure overnight at room tempera-
ture prior to visualization using the Zeiss Axioplan
Digital Deconvolution Microscope (Carl Zeiss, Inc.,
North America) and Slidebook software program
(Olympus, Center Valley, PA).
2.5 Inhibitors
Time course phosphorylation assays were first con-
ducted on VEC in the presence of insulin or TNFa
alone in order to determine the time points at which
phosphorylation of intracellular kinase intermediates
were activated. Subsequently, dose response analyses
were performed in order to determine half maximal
inhibitory concentrations (IC50) for inhibitors.
2.6 Flow Cytometry
Cells were grown in CGM until 75% confluence. Growth
medium was replaced with serum-free medium (SFM)
for 24 hours. Cells were incubated in SFM without or
with insulin or TNF-alpha alone or in combination for
indicated times. Cells were carefully lifted from culture
plates using Nozyme (Sigma, St. Loius, MO.). Cell
counts were performed using Trypan blue and a hemo-
cytometer. Equal numbers of cells (2 × 10
6 cells) from
each treatment group were placed into 1.5 mL Eppen-
dorf tubes. Cells were centrifuged at 500 × g for 6 min.
The supernatants were removed and cells were resus-
pended in 100 uL of SFM. Four microliters of VCAM-1/
FITC conjugated primary antibodies (BD Biosciences,
San Jose, CA) were added to each 100 uL of cell suspen-
sion containing 2 × 10
6 cells (otherwise 2 μL of antibody
per 1 × 10
6 cells) and incubated on ice for 30 min. Two
milliliters of Fluorescence Activated Cell Sorting (FACS)
solution [1% BSA in PBS] were added to the cold cell
antibody solution followed by centrifugation at 500 × g
for 6 min. The supernatant was removed and cells were
resuspended in two milliliters of FACS solution in order
to remove non-specific binding antibodies. This process
was repeated once more and supernatant was removed
and replace with 200 μL of 1% paraformaldehyde (PFA)
in FACS. The cell suspension was incubated on ice for
15 min and then read at 488 nm on a BD LSRII flow
cytometer (BD Bioscience, San Jose, CA).
2.7 Nuclear and Cytoplasmic Fraction Separation Assays
We performed nuclear extraction methodology as per pro-
tocol instructions in the kit from Pierce/Thermo-Fisher
(Cat# P78835). Briefly, once cells were treated with the
designated inhibitors and/or insulin and TNFa, cells were
washed with phosphate buffer solution (PBS) twice and
then cells were dislodge in 1 mL of PBS and transferred to
1.5 mL centrifuge tubes. Cells were centrifuged at 4°C at
500 × g. Several lysis buffers were used to sequentially dis-
rupt the plasma membrane only and then the nuclear
membrane with intermittent centrifugations in order to
isolate cytoplasmic and nuclear fractions of NFB.
2.8 Statistical Analysis
Data were analyzed by either unpaired Student’s t test
(two groups) or ANOVA with subsequent Tukey post
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than 0.05 was considered significant. Results were
expressed as the mean ± SEM of three or more inde-
pendent experiments.
Results
Insulin (10 nM) (Figure 1A) or TNFa (20 ng/mL) (Figure
1B) alone moderately, but significantly (P < 0.05) increased
VCAM-1 expression in vascular endothelial cells (VEC) in
a time-dependent manner. More importantly in the pre-
sence of insulin and TNFa together, VCAM-1 protein
content was significantly (P < 0.05) greater than that seen
for insulin or TNFa alone (Figure 1C).
Since insulin- or TNFa-stimulated increases of
VCAM-1 proteins were noted at short time periods we
wanted to examine what time frames were necessary in
order for insulin and TNFa to cause translocation of
VCAM-1 protein from the peri-nuclear region to the
cell surface, using immunofluorescence microscopy.
Insulin or TNFa alone stimulated the translocation of
VCAM-1 from the peri-nuclear region to the cell sur-
face. Unlike the short time frames that were observed
associated with insulin and TNFa-stimulated increases
in protein content, insulin (Figure 2) or TNFa induced
(Figure 3) movement of VCAM-1 to the cell surface
occurred over longer time periods; notably hours. Upon
further observation, we noticed two interesting results.
First, in the presence of insulin and TNFa together (Fig-
ure 4), the movement of VCAM-1 from the peri-nuclear
region to the cell surface occurred in a shorter amount
of time (one hour instead of two) as compare to that
seen for insulin or TNFa alone. Second, we observed a
stronger signal (i.e., an increased amount of VCAM-1)
at the cell surface in the presence of insulin and TNFa
together as compared to insulin or TNFa alone. Similar
assays were performed using flow cytometry and similar
results were observed (Figure 5).
Since insulin and TNFa are different biological mole-
cules, we wanted to determine which intra-cellular path-
ways mediated insulin and TNFa-stimulated VCAM
expression. In order to do so, we used PD98059
(MEK1/2 inhibitor), Wortmannin (PI3K inhibitor),
SB203580 (p38 MAPK inhibitor) and SP600125 (c-jun
Figure 1 Insulin and Tumor Necrosis Factor-alpha (TNFa)
stimulate increases in VCAM-1 expression in vascular
endothelial cells (VEC). Cells were incubated in growth medium
until 80% confluent. Growth medium was removed from cultured
cells and replaced with serum-free medium for 24 h. Cells were
treated without or with [A] insulin (INS) (10 nM), [B] TNFa (20 ng/
mL) or [C] both for designated times and VCAM-1 protein
expression was determined via Western blot analysis. Western blots
are representative profiles of six assays. [D] Changes in VCAM-1
protein are expressed as the percent of control and represent the
mean ± standard error of the mean (SEM) for six independent
experiments. *, P < 0.05 vs controls (serum-free medium alone); **,
P < 0.05 vs TNFa alone.
Figure 2 Insulin stimulates VCAM-1 protein translocation from
peri-nuclear to the cell surface in VEC. Cells were plated onto
round glass cover slips and allowed to proliferate in growth
medium until 50% confluence. Growth medium was replaced with
serum-free medium for 24 h. Cells were treated without or with
insulin (10 nM) for indicated times. Cells were fixed and treated
with primary and secondary antibodies as noted in the Methods
section. Immunofluorescence was observed using deconvolution
microscopy. VCAM-1 proteins are noted in green. Bars in pictures
represent 20 μm.
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kinase pathways were being activated by insulin and
TNFa with reference to VCAM-1 expression.
Using the information gathered from our time-course
and dose-response experiments (Table 1) we performed
assays to determine the effects of these inhibitors on
insulin or TNFa alone induced VCAM-1 expression or
i nt h ep r e s e n c eo fb o t ha n a l o g s( i n s u l i np l u sT N F a)
(Figure 6). We first examined the effects of the inhibi-
tors alone. The kinase inhibitors had no effect on
VCAM-1 expression after one hour of incubation time
plus the additional ten minute “no analog/analog” treat-
ment time (Figure 6A). However, in the presence of
insulin or TNFa alone or in combination thereof, only
the JNK inhibitor SP600125 significantly (P < 0.05)
inhibited expression of VCAM-1 as compared to posi-
tive controls (i.e., designated analog with no inhibitor).
Both the PI3K inhibitor Wortmannin and the p38 inhi-
bitor SB203580 moderately inhibited insulin or TNFa-
stimulated VCAM-1 expression, but without statistical
significance.
Figure 3 TNFa stimulates VCAM-1 protein translocation from
peri-nuclear to the cell surface in VEC. Cells were plated onto
round glass cover slips and allowed to proliferate in growth
medium until 50% confluence. Growth medium was replaced with
serum-free medium for 24 h. Cells were treated without or with
TNFa (20 ng/mL) for indicated times. Cells were fixed and treated
with primary and secondary antibodies as noted in the Methods
section. Immunofluorescence was observed using deconvolution
microscopy. VCAM-1 proteins are noted in green. Bars in pictures
represent 20 μm.
Figure 4 Insulin plus TNFa stimulate VCAM-1 protein
translocation from peri-nuclear to the cell surface in VEC. Cells
were plated onto round glass cover slips and allowed to proliferate
in growth medium until 50% confluence. Growth medium was
replaced with serum-free medium for 24 h. Cells were treated with
insulin (10 nM) and TNFa (20 ng/mL) in combination for indicated
times. Cells were fixed and treated with primary and secondary
antibodies as noted in the Methods section. Immunofluorescence
was observed using deconvolution microscopy. VCAM-1 proteins
are noted in green. Negative control of secondary antibody alone is
noted in the upper left quadrant. Bars in pictures represent 20 μm.
Figure 5 Either insulin or TNFa alone or in combination
stimulate VCAM-1 protein translocation from peri-nuclear to
the cell surface in VEC. Graph of flow cytometry results. Cells were
prepared for flow cytometry as described in Methods. Increased cell
surface VCAM-1 is expressed as percent of controls and represents
the mean ± S.E.M. of four experiments. *, P < 0.05 vs controls
(serum-free medium alone).
Table 1 Kinase inhibitors designated by common
nomenclature, noting target kinase and IC50
INHIBITOR TARGET IC 50 (μM)
PD98059 MEK1/2 10
WORTMANNIN PI3K 15
SB203580 p38 0.1
SP600125 JNK 25
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that seemed counter intuitive. The first event was the
influence of PD98059 on VCAM-1 protein expression.
The MEK1/2 inhibitor PD98059 significantly (P < 0.05)
increased VCAM-1 expression 50% above controls
(serum-free medium alone) in the presence of insulin
(Figure 6B) or TNFa (Figure 6C) alone. However, in the
presence of both insulin and TNFa (Figure 6D), the
MEK1/2 inhibitor (PD98059) significantly (P < 0.05)
increased VCAM-1 expression only 35% above controls
(serum-free medium alone).
The second event that piqued our interest was the
effect of Wortmannin on VCAM-1 expression in the
presence of insulin and TNFa, together. In the presence
of Wortmannin cells treated with insulin or TNFa alone
showed no significant decrease in VCAM-1 expression
as compared to controls (insulin or TNFa alone). How-
ever, in the presence of insulin and TNFa together,
Wortmannin significantly (P < 0.05) increased VCAM-1
expression 50% above negative controls and 30% above
positive controls (Figure 6D).
To further our investigation, we decided to examine
t h er o l eo fN F Bi ni n s u l i na n dT N F a-stimulated
VCAM-1 expression. Since NFB is correlated with
inflammation, we wondered whether or not NFBw a s
regulated by insulin and/or TNFa and one of our
selected kinase pathways. It has been shown that Hepa-
tocyte Growth Factor (HGF) suppresses vascular
endothelial growth factor-induced expression of
endothelial VCAM-1 by inhibiting the NFBp a t h w a y
[15]. Thus, we wanted to determine the affects of insulin
and TNFa on NFBi nV E Ca n dw h e t h e ro rn o to u r
selected inhibitors would perturb this signaling.
We observed that individually, insulin (Figure 7A) or
TNFa (Figure 7B) significantly (P < 0.05) stimulated
NFB nuclear import by 60 and 120 minutes, respec-
tively. Interestingly, in the presence of insulin and
TNFa concurrently, nuclear import of NFB was signifi-
cantly (P < 0.5) increased at 30 minutes as compared to
insulin or TNFa alone, and was sustained for a longer
period of time (Figure 7C). Cells not treated with insulin
or TNFa or both, exhibited no significant change over
time as compared to negative controls (Figure 7D).
We then pre-incubated the cells with either no inhibi-
tor, PD98059, Wortmannin, SB203580 or SP600125 for
one hour and then treated the same cells with either no
analog or with insulin and/or TNFa for 60 min. We first
noted that the in the presence of the inhibitors alone
(Figure 8A) there was no significant change in percent
nuclear NFB as compared to negative controls (Figure
8B, lane1). We also observed that in the presence of the
inhibitors insulin or TNFa-stimulated NFB nuclear
import was either not affected or was moderately, but
not statistically attenuated as compared to positive con-
trols (not shown). In contrast, the PI3K inhibitor, Wort-
mannin, increased insulin plus TNFa-stimulated NFB
nuclear import significantly (P < 0.02) above that seen for
positive controls (insulin or TNFa alone with no
Figure 6 The role of kinase pathways in VCAM-1 expression in
VEC treated without or with insulin or TNFa alone or both and
in the absence or presence of kinase inhibitors. Cells were
grown to 80% confluence in growth medium. Growth medium was
replaced with serum-free medium for 24 h. Cells were pre-treated
with either no inhibitor, PD98059 (10 μM), Wortmannin (15 μM),
SB203580 (100 nM) or SP600125 (25 μM) for one hour and then
treated without or with insulin (10 nM) or TNFa (20 ng/mL) alone,
or insulin plus TNFa for 10 additional minutes. Proteins from cleared
lysates were analyzed by SDS-PAGE and determined by Western
blot analysis for VCAM-1 expression. Representative Western blots of
VCAM-1 expression are shown in the absence or presence of
indicated inhibitors [Panel A] and without or with insulin (INS)
[Panel B] or TNFa [Panel C] alone, or without or with insulin plus
TNFa [Panel D]. [Panel E, graph] Changes in amounts of VCAM-1
protein in the absence or presence of inhibitors and without or
with insulin or TNFa, or insulin plus TNFa are expressed as percent
of controls and are represented as means ± SEM of 5 experiments.
*, P < 0.05 vs controls (serum-free medium alone); **, P < 0.05 vs
positive controls (insulin or TNFa with no inhibitor). #, P < 0.05 vs
insulin plus TNFa (no inhibitors). (SFM) serum-free medium; (INHB)
inhibitors; (NI) no inhibitors; (INS) insulin; (TNFa) Tumor Necrosis
Factor-alpha; (PD) PD98059; (WT) Wortmannin; (SB) SB203580; and
(SP) SP600125.
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seen for TNFa alone with WT (Figure 8C).
Disucussion
In the United States alone there are 23.6 million people
reported to have diabetes with countless more undiag-
nosed individuals. T2DM is a syndrome of multiple dis-
orders that starts with insulin resistance and eventually
leads to a plethora of pathologies. Vascular complica-
tions are the most prevalent pathology found associated
with T2DM. Insulin resistance and hyperinsulinemia are
risk factors for cardiovascular diseases (CVD) [1,16], and
in time and left unchecked CVD will lead to loss of
limb and life. A particular vascular event that occurs in
diabetes is increased expression of cellular adhesion
molecules on the surface of vascular endothelial cells.
VCAM-1 is one such adhesion molecule that is upregu-
lated in the state of insulin resistance and hyperinsuline-
mia. Its upregulation leads to inflammatory effects and
remodeling of the vessel, contributing to the occlusion
of the arterial lumen.
Figure 7 Effects of insulin and/or TNFa on nuclear import of
NFB in VEC. Cells were grown to 80% confluence in growth
medium. Cultures were subsequently grown in serum-free medium
for 24 hours and then treated without or with (INS) insulin (10 nM)
or TNFa (20 ng/mL) alone or in combination for indicated times.
Cytoplasmic and nuclear fractions were isolated and relative
amounts of NFB were determined. Representative western blots of
cells treated without or with (INS) insulin [Panel A], TNFa [Panel B]
or insulin plus TNFa (INS/TNFa) together [Panel C] are shown.
Cytoplasmic (C) and nuclear (N) fractions are shown at indicated
times. [Panel D] Relative amounts of NFB are expressed as percent
nuclear [(Nuc)/(Cyt + Nuc) * 100] at designated times and represent
the mean ± SEM of 4 separate experiments. *, P < 0.05 vs controls
(serum-free medium alone). (NA) no analog.
Figure 8 Effects of kinase inhibitors on insulin augmented
TNFa-stimulated NFB nuclear import. VEC were cultured in
growth medium until 80% confluent and then cultured in serum-
free medium for 24 h. Thereafter, cells were pre-treated with no
inhibitor, PD98059 (10 μM), Wortmannin (15 μM), SB203580 (100
nM) or SP600125 (25 μM) for one hour and then treated with no
analog (NA)(i.e., no insulin or TNFa) or with insulin (10 nM), TNFa
(20 ng/mL) alone or in combination for 60 minutes. Representative
Western blots at time 60 minutes are shown noting changes in
relative NFB protein content in cytoplasmic (C) and nuclear (N)
fractions of cells treated with designated inhibitors alone [Panel A]
or without or with inhibitors and in the absence or presence of
insulin plus TNFa [Panel B]. [Panel C] Percentage of nuclear NFBi s
expressed for cells treated with either no analog (NA) (open bars) or
presence of insulin (striped bars) or TNFa (shaded bars) alone, or
insulin plus TNFa (solid bars) and in the absence or presence of
indicated inhibitor. Graph represents the mean ± SEM for 5 separate
experiments. (NA) no analog; (NO INHB) no inhibitor; (INS) insulin;
(TNFa) Tumor necrosis factor-alpha; (INS + TNFa) insulin plus TNFa;
(PD) PD98059; (WT) Wortmannin; (SB) SB203580; (SP) SP600125. *, P
< 0.05 vs controls (no analog no inhibitor; serum-free medium
alone); **, P < 0.05 vs TNFa plus WT.
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responses. Some have reported that this cell surface
molecule is important in bacterial and viral defense
mechanisms [17]. Yet, more importantly is its role in
inflammation. VCAM-1 binds to integrins, which are
found on the surface of cells belonging to the immune
system such as leukocytes, lymphocytes and monocytes
[18]. These immune-response cells are the scavengers of
the circulatory system. When they are activated, they
express their own surface adhesion markers, which in
turn are recognized by cellular adhesion molecules that
are located on the surface of the endothelial cells of the
intima. Activated immune cells translocate into the vas-
cular tissue and away from the circulatory system
whereby they secrete inflammatory cytokines and induce
the sequelae of inflammation and vascular wall
remodeling.
Another aspect of VCAM-1 activity has been observed
in the presence of oxidized lipids [10]. Oxidized lipids
assist in the upregulation of VCAM-1 expression,
whereby adhesion of leukocyte and monocytes to the
endothelium membrane increases [18]. In both cases,
transendothelial migration of leukocytes and monocytes
occurs, causing the secretion of inflammatory cytokines
and chemokines. One such cytokine is TNFa, which not
only is secreted by mature monocytes (i.e., macro-
phages), but also by perturbed endothelial cells [19].
TNFa is a well characterized inflammatory cytokine
and its presence is strongly correlated with atherogen-
esis [8,20]. In contrast, insulin’s role in atherogenesis
has been a hotly debated topic. On the one hand, some
contend that insulin stimulates the increase of nitric
oxide (NO) and decreases systemic inflammation [5,21],
which in turn may inhibit atherogenesis. On the other
hand, others argue that insulin, especially in the context
of hyperinsulinemia, increases the proliferation of
endothelial and vascular smooth muscle cells and
exacerbates the inflammatory response [22,23]. Yet, if
one looks at this argument, the two sides are not con-
tradictory. Insulin appears to have a “double-phase”
effect. At physiologic concentrations, insulin has a vas-
cular protective effect [5]. However, at hyper-physiologic
concentrations, insulin appears to have a vascular insult
effect, by augmenting the effects of deleterious cyto-
kines. It has been demonstrated that high physiologic
insulin levels may inhibit endothelial progenitor cell
proliferation [24,25]. In contrast, hyper-physiologic insu-
lin appears to augment more potent growth factors such
as platelet-derived growth factor [12,26] thereby causing
a destructive effect on the endothelium.
VCAM-1 plays a more dominant role in atherosclero-
sis than ICAM-1 [27]. Yet, both appear to increase in
expression within the context of insulin resistance and
hyperinsulinemia. One possible mechanism for increased
expression of CAMs is insulin’s ability to prime cells to
be more responsive to more potent cytokines, which in
turn complement the insulin resistant state and thereby
increase CAM expression [28]. Previous studies have
associated hyperinsulinemia with atherosclerosis [29-31].
Additionally, CAM expression has been linked to
inflammatory conditions that appear to be correlated
with atherosclerosis [32,33]. Other investigators have
posited that insulin resistance and hyperinsulinemia may
contribute to the increased expression of TNFa,
whereby pro-inflammatory mechanisms are increased in
the presence of insulin resistance [34].
We have shown in this study that high-physiological
concentrations of insulin increase the expression of
VCAM-1 above that seen for quiescent cells. In compar-
ison, TNFa alone stimulates increases in the expression
of VCAM-1 above that seen for controls and insulin.
What is impressive is the affect of insulin on TNFa-sti-
mulated increases in VCAM-1 expression. In the pre-
sence of insulin and TNFa concurrently, stimulation of
VCAM-1 expression is greater than that seen for TNFa
alone. Additionally, in the presence of insulin and TNFa
simultaneously, translocation of VCAM-1 protein from
peri-nuclear regions to the cell surface occurs faster
than that seen with cells in the presence of either insu-
lin or TNFa alone.
The path from hormone and cytokine to intracellular
kinase pathway has always been intriguing and there is
no exception in this study. In what appears to be simple
inhibitor assays, the JNK inhibitor SP600125 appears to
be the major regulated kinase pathway for insulin and
TNFa stimulation of VCAM-1 expression. Yet, what
became most interesting in this study were the changes
in VCAM-1 expression in cells pre-treated with
PD98059 (MEK1/2 inhibitor) and Wortmannin (PI3K
inhibitor). In the presence of insulin or TNFa alone,
PD98059 stimulated an increase in VCAM-1 expression
50% above controls. In the presence of insulin or TNFa
alone, Wortmannin had moderate, but statistically insig-
nificant, inhibition of insulin- or TNFa-stimulated
VCAM-1 expression. In contrast, in the presence of
insulin and TNFa together, cells pre-treated with Wort-
mannin exhibited a 50% increase in VCAM-1 expression
above negative controls (serum-free medium alone) and
30% above that seen for insulin and TNFa together in
the absence of an inhibitor. Taken together, these results
indicate that (1) cross talk occurs among the major
kinase pathways, (2) inhibition of one kinase pathway
may disinhibit another, and (3) hyperinsulinemia in con-
junction with insulin resistance’s canonical perturbed
pathway (PI3K) exacerbates TNFa-stimulated increases
in VCAM-1.
Since insulin and TNFa appear to be associated with
inflammation of the arterial endothelium, we were
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any of the major intracellular kinase pathways that were
stimulated by insulin and TNFa would affect the cano-
nical inflammation player, NFB. We used kinase inhibi-
tors to determine their influences on insulin and TNFa
stimulated nuclear import of NFB in endothelial cells.
While MEK1/2, p38 and JNK inhibitors reduced insulin
and TNFa-stimulated NFB nuclear import, the PI3K
inhibitor Wortmannin significantly (P < 0.05) increased
NFB nuclear import in cells treated with insulin or
TNFa. In fact, in the presence of both insulin and
TNFa, nuclear import of NFBw a sg r e a t e rt h a nt h a t
seen in the presence of insulin or TNFa alone and
occurred more quickly than that seen for either one
alone.
It should be kept in mind that these studies were per-
formed in a rat aorta vascular endothelial cell line.
Thus, it would be of interest to perform the same
experiments in primary cell cultures in order to deter-
mine whether or not these observations hold true for
primary endothelial cells as well. Thus, future studies
are warranted.
Taken together, these results indicate that insulin can
be atherogenic, can augment TNFa-stimulated VCAM-1
expression and thus play a key role in vascular inflam-
mation. Additionally, our data show that although insu-
lin- and TNFa-stimulated increases of VCAM-1 appear
to be regulated by the JNK pathway, perturbation of the
PI3K pathway (a common insulin resistant effect) greatly
increased the amount and rate of insulin and TNFa-sti-
mulated NFB nuclear import; a precursor event to
increased inflammatory sequelae.
Conclusions
Hyperinsulinemia and a perturbed PI3K pathway
appear to augment TNFa stimulation of VCAM-1 pro-
tein, VCAM-1 translocation to the cell surface and
nuclear import of NFB. These results taken together
indicate that hyperinsulinemia, insulin resistance and
perturbed PI3K signaling, which are hallmarks of
Type-2 Diabetes Mellitus, may exacerbate the inflam-
matory conditions that are affected by TNFa and may
play important roles in the pathogenesis of
atherosclerosis.
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